MCID: BCT013
MIFTS: 47

Bacterial Pneumonia

Categories: Blood diseases, Infectious diseases, Respiratory diseases

Aliases & Classifications for Bacterial Pneumonia

MalaCards integrated aliases for Bacterial Pneumonia:

Name: Bacterial Pneumonia 12 73 15 17
Pneumonia Due to Other Gram-Negative Bacteria 12
Gram-Negative Pneumonia 12
Pneumonia, Bacterial 44
Pneumonia Bacterial 54

Classifications:



External Ids:

Disease Ontology 12 DOID:874
ICD9CM 34 482.9
MeSH 44 D018410
NCIt 50 C26704
SNOMED-CT 67 53084003
ICD10 32 J15 J15.9
UMLS 70 C0004626

Summaries for Bacterial Pneumonia

Disease Ontology : 12 A pneumonia involving inflammation of the lungs caused by bacteria.

MalaCards based summary : Bacterial Pneumonia, also known as pneumonia due to other gram-negative bacteria, is related to chlamydia pneumonia and klebsiella pneumonia. An important gene associated with Bacterial Pneumonia is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions. The drugs Oseltamivir and Ceftriaxone have been mentioned in the context of this disorder. Affiliated tissues include lung, neutrophil and skin.

Wikipedia : 73 Bacterial pneumonia is a type of pneumonia caused by bacterial infection... more...

Related Diseases for Bacterial Pneumonia

Diseases in the Pneumonia family:

Viral Pneumonia Bacterial Pneumonia

Diseases related to Bacterial Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 461)
# Related Disease Score Top Affiliating Genes
1 chlamydia pneumonia 32.3 IL6 CXCL8 CRP
2 klebsiella pneumonia 32.3 IL6 CXCL8 CXCL1 CRP
3 aspiration pneumonia 32.3 IL6 GPT CRP
4 streptococcus pneumonia 32.2 IL6 CXCL8 CRP
5 mycoplasma pneumoniae pneumonia 32.2 SFTPD IL6 CRP
6 pneumonia 31.8 SLPI SFTPD SFTPB SCGB1A1 IL6 IL22
7 chlamydia 31.3 IL6 CXCL8 CRP
8 bacterial infectious disease 31.2 IL6 ELANE DEFB4A CXCL8 CSF3 CRP
9 viral pneumonia 31.1 SFTPD IL6 CXCL8 CRP
10 toxic shock syndrome 31.0 IL6 HMGB1 CXCL8 CRP
11 pleural empyema 31.0 IL6 GPT CRP
12 bronchiectasis 30.9 SLPI ELANE CXCL8 CRP
13 pulmonary edema 30.8 SCGB1A1 CXCL8 CSF3 CRP
14 bronchopneumonia 30.7 IL6 GPT ELANE CXCL8 CRP CCL3
15 oral candidiasis 30.7 SLPI DEFB4A CXCL8
16 respiratory failure 30.6 SFTPD SFTPB SCGB1A1 IL6 GPT ELANE
17 diarrhea 30.6 IL6 GPT CXCL8 CSF3 CALCA
18 endocarditis 30.6 IL6 CXCL8 CRP
19 invasive aspergillosis 30.5 SFTPD CXCL8 CSF3
20 candidiasis 30.5 IL6 IL22 DEFB4A CXCL8
21 severe acute respiratory syndrome 30.5 IL6 CXCL8 CRP
22 meningitis 30.5 IL6 CXCL8 CXCL1 CSF3 CRP CCL3
23 peritonitis 30.5 IL6 ELANE CXCL8 CXCL1 CRP CCL3
24 pneumocystosis 30.5 SFTPD IL6 CSF3 CRP
25 exanthem 30.5 IL6 GPT CXCL8 CSF3 CRP
26 immune deficiency disease 30.5 SLPI IL6 HMGB1 GPT CXCL1 CRP
27 liver cirrhosis 30.5 SLPI IL6 GPT CXCL8 CRP
28 acute cystitis 30.5 IL6 GPT CXCL8 CXCL1 CRP
29 aspergillosis 30.5 SFTPD IL6 ELANE CXCL8 CSF3 CCL3
30 bronchitis 30.4 SLPI IL6 ELANE CXCL8 CRP
31 disseminated intravascular coagulation 30.4 IL6 HMGB1 GPT ELANE CRP
32 tracheitis 30.4 IL6 CXCL8 CRP
33 pasteurellosis 30.4 SLPI ELANE CXCL8
34 neutropenia 30.4 IL6 GPT ELANE CXCL8 CSF3 CRP
35 respiratory syncytial virus infectious disease 30.4 SFTPB CCL3
36 pulmonary fibrosis 30.4 SFTPD ELN ELANE CXCL8 CCL3
37 pericardial effusion 30.4 IL6 GPT CRP
38 cholangitis 30.3 IL6 GPT CXCL8 CRP
39 acute cholangitis 30.3 IL6 GPT CRP CALCA
40 bacterial meningitis 30.3 IL6 CXCL8 CXCL1 CRP
41 gastritis 30.3 IL6 DEFB4A CXCL8 CXCL1
42 bilirubin metabolic disorder 30.3 IL6 GPT CSF3 CRP
43 varicose veins 30.3 IL6 ELN CXCL8
44 hemopericardium 30.3 ELN CRP
45 osteomyelitis 30.3 IL6 CXCL8 CSF3 CRP CALCA
46 disease by infectious agent 30.3 SFTPD IL6 GPT DEFB4A CRP CCL3
47 bacterial sepsis 30.3 IL6 ELANE CXCL8 CRP CALCA
48 avian influenza 30.3 SFTPD IL6 CXCL8
49 thrombocytosis 30.3 IL6 CSF3 CRP
50 proteasome-associated autoinflammatory syndrome 1 30.3 IL6 ELANE CXCL8 CRP CCL3

Graphical network of the top 20 diseases related to Bacterial Pneumonia:



Diseases related to Bacterial Pneumonia

Symptoms & Phenotypes for Bacterial Pneumonia

Drugs & Therapeutics for Bacterial Pneumonia

Drugs for Bacterial Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
2
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
3
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
4
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
5
Vancomycin Approved Phase 4 1404-90-6 441141 14969
6
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
7
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
8
Nevirapine Approved Phase 4 129618-40-2 4463
9
Zidovudine Approved Phase 4 30516-87-1 35370
10
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
11
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
12 Cephalosporins Phase 4
13 Antiviral Agents Phase 4
14 Clavulanic Acids Phase 4
15 Amoxicillin-Potassium Clavulanate Combination Phase 4
16 Liver Extracts Phase 4
17 Anti-Retroviral Agents Phase 4
18 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
19 Clindamycin palmitate Phase 4
20 Clindamycin phosphate Phase 4
21
Cefuroxime Approved Phase 2, Phase 3 55268-75-2 5361202 5479529
22
Daptomycin Approved, Investigational Phase 3 103060-53-3 16129629
23
Delafloxacin Approved, Investigational Phase 3 189279-58-1
24
Telavancin Approved Phase 3 372151-71-8
25
Ceftolozane Approved, Investigational Phase 3 689293-68-3
26
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
27
Sulbactam Approved Phase 3 68373-14-8
28
Cilastatin Approved, Investigational Phase 3 82009-34-5 5280454 6435415
29
Imipenem Approved Phase 3 64221-86-9, 74431-23-5 104838
30
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
31
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
32
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
33
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
34
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
35
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 439-14-5 3016
36
Aztreonam Approved Phase 2, Phase 3 78110-38-0 5362041 5742832
37
Ampicillin Approved, Vet_approved Phase 2, Phase 3 69-53-4 6249
38
Ofloxacin Approved Phase 3 82419-36-1 4583
39
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
40
Amikacin Approved, Investigational, Vet_approved Phase 3 37517-28-5 37768
41
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
42
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
43
Doripenem Approved, Investigational Phase 3 148016-81-3 73303
44
Erythromycin Approved, Investigational, Vet_approved Phase 2, Phase 3 114-07-8 12560
45
Colistin Approved Phase 3 1066-17-7, 1264-72-8 5311054
46
Lysine Approved, Nutraceutical Phase 2, Phase 3 56-87-1 5962
47
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
48
Solithromycin Investigational Phase 2, Phase 3 760981-83-7
49
Murepavadin Investigational Phase 3 944252-63-5
50 Pharmaceutical Solutions Phase 3

Interventional clinical trials:

(show top 50) (show all 127)
# Name Status NCT ID Phase Drugs
1 Individualizing Duration of Antibiotic Therapy in Hospitalized Patients With Community - Acquired Pneumonia: a Non-inferiority, Randomized, Controlled Trial. Unknown status NCT01492387 Phase 4
2 Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18) Completed NCT01248715 Phase 4 oseltamivir
3 Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (CABP) Completed NCT01524302 Phase 4 Ceftaroline;Levofloxacin
4 A Multicenter, Multinational, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil Versus Ceftriaxone Plus Vancomycin in Adult Subjects With Community-acquired Bacterial Pneumonia at Risk for Infection Due to Methicillin-resistant Staphylococcus Aureus Completed NCT01645735 Phase 4 Ceftaroline fosamil;Ceftriaxone plus vancomycin
5 Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
6 Evaluation of World Health Organization (WHO) Recommendations on Test and Treat Strategy, Managing Advanced HIV Disease and Rapid Initiation of ART Among People Living With HIV in Nepal: A Cluster Randomized Trial. Completed NCT03723525 Phase 4
7 A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone Plus Vancomycin in Pediatric Subjects With Complicated Community-acquired Bacterial Pneumonia (CABP) Completed NCT01669980 Phase 4 Ceftaroline fosamil;IV Ceftriaxone and Vancomycin
8 A Multicenter Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Elderly Subjects With Community-Acquired Bacterial Pneumonia Withdrawn NCT01666743 Phase 4 Ceftaroline fosamil
9 Randomized Aseptic Pharmacokinetic Pharmacodynamic Outpatient Registry Trial of Respiratory Tract Infections in Adults (RAPPORT) Withdrawn NCT00245453 Phase 4 azithromycin;telithromycin;Clarythromycin
10 The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia Unknown status NCT01865266 Phase 2, Phase 3 Ulinaststin for injection;placebo
11 A Phase III Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia Unknown status NCT01937832 Phase 3 Faropenem;Ertapenem
12 Phase 3b Randomized Double Blind Controled Placebo Comparative Trial of Intravenous Colistin vs Intravenous Colistin Plus Nebulized Colistin in Patients With Ventilator-associated Pneumonia (VAP) Due Multiresistant Acinetobacter Baumanii Unknown status NCT00645723 Phase 3 Colistin;Colistin and saline solution
13 A Multicenter, Unblinded, Non-Comparative Study Of Unasyn-S 12 G/Day Evaluating The Safety And Efficacy In Japanese Adult Subjects With Community Acquired Pneumonia Completed NCT01189487 Phase 3 ampicillin sodium/sulbactam sodium
14 Ceftaroline Fosamil Versus Standard of Care for Community Acquired Bacterial Pneumonia (CABP): Clinical Outcomes Among Hospitalized Adults at a Single United States Hospital Completed NCT01605864 Phase 3 Efficacy of ceftaroline
15 A Multicenter, Active-Controlled, Randomized Study To Evaluate The Safety And Efficacy Of Levofloxacin Versus Ceftriaxone Sodium Or Cefuroxime Axetil In The Treatment Of Community-Acquired Pneumonia In Adults Completed NCT00257049 Phase 2, Phase 3 levofloxacin
16 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia Completed NCT01799993 Phase 3 Amikacin Inhalation Solution (BAY41-6551);Aerosolized Placebo
17 A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia Completed NCT02493764 Phase 3 Imipenem;Relebactam;Cilastatin;Piperacillin;Tazobactam;Linezolid
18 A Randomized, Double-Blind, Phase III, Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae Completed NCT00538694 Phase 3 daptomycin
19 Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae Completed NCT00540072 Phase 3 daptomycin
20 A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone in the Treatment of Adult Subjects With Community-Acquired Pneumonia Completed NCT00509106 Phase 3 Ceftaroline fosamil for Injection;Ceftriaxone;Placebo
21 A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia Completed NCT02679573 Phase 3 Delafloxacin;Moxifloxacin;Linezolid
22 Randomized, Open Label, Multicenter, Non-inferiority Trial to Compare Safety and Efficacy of Colistin vs. Meropenem in VAP Caused by CR-GNB Completed NCT01292031 Phase 3 Colistin;Meropenem
23 A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone, With Adjunctive Clarithromycin, in the Treatment of Adult Subjects With Community-Acquired Pneumonia Completed NCT00621504 Phase 3 Ceftaroline fosamil for Injection;IV Ceftriaxone;Placebo;Clarithromycin
24 A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia Completed NCT02531438 Phase 3 Omadacycline;Moxifloxacin
25 A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia Completed NCT01371838 Phase 3 Ceftaroline;Ceftriaxone
26 A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Imipenem/Cilastatin For The Treatment Of Subjects With Nosocomial Pneumonia Completed NCT00080496 Phase 3 Tigecycline;Imipenem;Cilastatin
27 Acute Respiratory Infections and Asthma in U-5 Children: Improved Treatment to Reduce Morbidity and Mortality in Uganda, A Randomized Controlled Trial Completed NCT01868113 Phase 3 Inhaled corticosteroid
28 A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia Completed NCT01756339 Phase 3 Solithromycin;Moxifloxacin
29 A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia Completed NCT01968733 Phase 3 Solithromycin;Moxifloxacin
30 A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus Completed NCT00124020 Phase 3 Telavancin;Vancomycin
31 Parapneumonic Effusion in Children Study Completed NCT00202826 Phase 3
32 A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus Completed NCT00107952 Phase 3 Telavancin;Vancomycin
33 A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Community-acquired Bacterial Pneumonia Requiring Hospitalization Completed NCT01530763 Phase 2, Phase 3 Ceftaroline fosamil;Ceftriaxone;amoxicillin clavulanate
34 A Prospective, Non-randomized, Open-label, Non-controlled, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics/ Pharmacodynamics of BAYQ3939 (400 mg BID and TID) in Hospitalized Patients With Bacterial Pneumonia or Secondary Infection of Chronic Respiratory Disease With Severe Disease or a Poor Response to Other Antimicrobials Completed NCT01561794 Phase 3 Ciprofloxacin (Cipro, BAYQ3939)
35 An International, Multicenter, Randomized, Double-blind, Double-dummy, Two-way, Parallel Group, Controlled Study to Compare the Efficacy and Safety of Intravenous and Oral Nemonoxacin Versus Tavanic® in Adult Patients With Community-acquired Pneumonia Completed NCT03551210 Phase 3 Nemonoxacin;Nemonoxacin;Tavanic;Tavanic;Placebo (250 ml);Placebo (100 ml)
36 A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia Completed NCT00081575 Phase 3 Tigecycline;Levofloxacin
37 A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia Completed NCT00079885 Phase 3 tigecycline
38 A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT02168946 Phase 3 Vabomere;Best Available Therapy
39 A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT01970371 Phase 3 plazomicin;colistin;meropenem;tigecycline;antibiotic of Investigator's choice
40 A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens Completed NCT03032380 Phase 3 Cefiderocol;Meropenem;Linezolid
41 A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared With Meropenem in Adult Patients With Ventilated Nosocomial Pneumonia Completed NCT02070757 Phase 3 Ceftolozane/tazobactam;Meropenem
42 A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia Completed NCT02559310 Phase 3 lefamulin;Moxifloxacin;Linezolid
43 A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC 3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia Completed NCT02813694 Phase 3 lefamulin;Moxifloxacin
44 A Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia Recruiting NCT03583333 Phase 3 IMI/REL FDC;PIP/TAZ FDC;Linezolid
45 A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP) Recruiting NCT04779242 Phase 3 Omadacycline;Moxifloxacin
46 To Assess the Role of Sphingosine-1-phosphate in the Pathobiology of Pneumonia: Generate a New Strategy for Treatment of Severe Community-acquired Pneumonia Recruiting NCT04007328 Phase 2, Phase 3 Methylprednisolone Sodium Succinate;Placebo
47 Reducing Antibiotics Treatment Duration for Ventilator-Associated Pneumonia Recruiting NCT03382548 Phase 3 Reducing Antibiotics treatment duration;Standard Antibiotics treatment duration
48 A Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex Recruiting NCT03894046 Phase 3 ETX2514/Sulbactam + Imipenem/Cilastin;Colistin + Imipenem/Cilastin;ETX2514/Sulbactam + Imipenem/Cilastin
49 Efficacy, Safety and Pharmacokinetics Profile of Nebulized Aztreonam Lysine (AZLI) for Prevention of Gram Negative Pneumonia in Heavily Colonized Mechanically Ventilated Patients Recruiting NCT03749226 Phase 2, Phase 3 Aztreonam lysine
50 A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia Terminated NCT01110421 Phase 3 Cefepime placebo;Cefepime;Doripenem;Doripenem placebo;Amoxicillin/clavulanate potassium

Search NIH Clinical Center for Bacterial Pneumonia

Cochrane evidence based reviews: pneumonia, bacterial

Genetic Tests for Bacterial Pneumonia

Anatomical Context for Bacterial Pneumonia

MalaCards organs/tissues related to Bacterial Pneumonia:

40
Lung, Neutrophil, Skin, Bone Marrow, Myeloid, Bone, Liver

Publications for Bacterial Pneumonia

Articles related to Bacterial Pneumonia:

(show top 50) (show all 3916)
# Title Authors PMID Year
1
Myeloperoxidase-dependent inactivation of surfactant protein D in vitro and in vivo. 54 61
20228064 2010
2
Prognostic value of C-reactive protein in HIV-infected patients with Pneumocystis jirovecii pneumonia. 61 54
20378904 2010
3
MyD88-dependent TLR4 signaling is selectively impaired in alveolar macrophages from asymptomatic HIV+ persons. 54 61
20197549 2010
4
2009 influenza A (H1N1): a clinical review. 54 61
20469616 2010
5
Is procalcitonin better than C-reactive protein for early diagnosis of bacterial pneumonia in children? 61 54
20087955 2010
6
Validity of the quick-read C-reactive protein test in the prediction of bacterial pneumonia in the pediatric emergency department. 54 61
18460957 2008
7
The utility of serum C-reactive protein in differentiating bacterial from nonbacterial pneumonia in children: a meta-analysis of 1230 children. 61 54
18174874 2008
8
Evaluation of serum amyloid A and surfactant protein D in sera for identification of the clinical condition of horses with bacterial pneumonia. 61 54
17827889 2007
9
Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. 61 54
17727748 2007
10
[Changes and clinical significance of Toll-like receptor 2 and 4 expression in neonatal infections]. 54 61
17456342 2007
11
Disease severity in patients with simultaneous influenza and bacterial pneumonia. 54 61
17603232 2007
12
[Clinical features and outcome in 84 patients with influenza pneumonia]. 54 61
17087332 2006
13
Neutrophil serine proteinases inactivate surfactant protein D by cleaving within a conserved subregion of the carbohydrate recognition domain. 61 54
15078883 2004
14
C-reactive protein in the diagnosis of community-acquired pneumonia. 61 54
14533984 2003
15
Correlations between serum amyloid A protein and C-reactive protein in infectious diseases. 61 54
12940634 2003
16
Bacterial pneumonia can increase serum concentration of clozapine. 54 61
12185555 2002
17
Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. 61 54
11818324 2002
18
Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. 54 61
11588011 2001
19
Procalcitonin in children admitted to hospital with community acquired pneumonia. 61 54
11259234 2001
20
Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. 54 61
10917215 2000
21
[A study of human beta-defensin-1 and human beta-defensin-2 in airway mucosal defense]. 54 61
10213993 1999
22
[Significance of serum surfactant protein-D (SP-D) level in patients with pulmonary tuberculosis]. 54 61
9844346 1998
23
Identification of human beta-defensin-2 in respiratory tract and plasma and its increase in bacterial pneumonia. 61 54
9731241 1998
24
Value of C-reactive protein in the detection of bacterial contamination at the time of presentation in drug-induced aspiration pneumonia. 61 54
9266885 1997
25
[Diagnostic value of serum soluble interleukin-2 receptor levels in interstitial pneumonia of the patients with hematological disorders]. 61 54
9059070 1997
26
Adenosine deaminase activity in the aetiological diagnosis of community-acquired pneumonia. 54 61
9255891 1997
27
[A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia]. 61 54
7783313 1995
28
[Diagnostic value of C-reactive protein in comparison with erythrocyte sedimentation as routine admission diagnostic test]. 61 54
7878400 1995
29
Possible low response of C-reactive protein production in eosinophilic pneumonia. 61 54
8735434 1995
30
Utility of C-reactive protein measurements for empyema diagnosis after pneumonectomy. 54 61
8166544 1994
31
The C-reactive protein responses in HIV-infected patients with pneumonia. 61 54
8362226 1993
32
[Studies on risk factors influencing delayed resolution of pneumonia]. 61 54
1294663 1992
33
Efficacy and safety of loracarbef in the treatment of pneumonia. 54 61
1621747 1992
34
[Pneumonia caused by Moraxella subgenus Moraxella sp]. 61 54
1624833 1992
35
Adenosine deaminase activity and free IL-2 receptor levels in serum from patients with mycoplasma pneumonia. 61 54
1907690 1991
36
Protective effects of Re-yan-ning mixture on Streptococcus pneumonia in rats based on network pharmacology. 61
33678123 2021
37
MANet: A two-stage deep learning method for classification of COVID-19 from Chest X-ray images. 61
33753962 2021
38
COVIDetection-Net: A tailored COVID-19 detection from chest radiography images using deep learning. 61
33551492 2021
39
Interleukin-33 improves local immunity during Gram-negative pneumonia by a combined effect on neutrophils and inflammatory monocytes. 61
33305354 2021
40
The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. 61
33587436 2021
41
Pharmacokinetics and Safety of Lefamulin After Single Intravenous Dose Administration in Subjects with Impaired Hepatic Function. 61
33811377 2021
42
Pharmacokinetics and Safety of Lefamulin After Single Intravenous Dose Administration in Subjects with Impaired Renal Function and those Requiring Hemodialysis. 61
33797776 2021
43
Successful Treatment of Life-Threatening COVID-19 Infection in a Face Transplant Recipient. 61
33661221 2021
44
Lightweight deep learning models for detecting COVID-19 from chest X-ray images. 61
33360271 2021
45
One-shot Cluster-Based Approach for the Detection of COVID-19 from Chest X-ray Images. 61
33680210 2021
46
Impaired antibacterial immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. 61
33791731 2021
47
Performance of national COVID-19 'symptom checkers': a comparative case simulation study. 61
33685943 2021
48
The Unyvero Hospital-Acquired pneumonia panel for diagnosis of secondary bacterial pneumonia in COVID-19 patients. 61
33661410 2021
49
A Cascade-SEME network for COVID-19 detection in chest c-ray images. 61
33778966 2021
50
The spatial landscape of lung pathology during COVID-19 progression. 61
33780969 2021

Variations for Bacterial Pneumonia

Expression for Bacterial Pneumonia

Search GEO for disease gene expression data for Bacterial Pneumonia.

Pathways for Bacterial Pneumonia

Pathways related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 SLPI S100A12 IL6 IL22 HMGB1 ELANE
2
Show member pathways
12.19 IL6 CXCL8 CXCL1 CCL3
3 12.1 IL6 DEFB4A CXCL8 CXCL1
4
Show member pathways
12.05 IL6 DEFB4A CXCL8 CXCL1 CSF3
5
Show member pathways
12.03 SFTPD IL6 DEFB4A CXCL8
6 11.76 IL6 CXCL8 CXCL1 CCL3
7 11.67 IL6 CXCL8 CXCL1 CCL3
8
Show member pathways
11.64 IL6 CXCL8 CXCL1 CSF3
9 11.48 IL6 CXCL8 CXCL1
10 11.4 IL6 CXCL8 CSF3
11 11.35 IL6 HMGB1 ELANE
12 11.1 IL6 CXCL1 CSF3
13 11.04 IL6 CXCL8 CXCL1 CSF3 CCL3
14 10.9 IL6 ELN CXCL8 CSF3 CCL3 CALCA
15 10.71 IL6 CXCL8 CRP
16 10.68 S100A12 HMGB1
17 10.6 IL6 IL22 ELN CXCL8 CXCL1 CSF3

GO Terms for Bacterial Pneumonia

Cellular components related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 SLPI SFTPD SFTPB SCGB1A1 S100A12 IL6
2 extracellular space GO:0005615 9.58 SLPI SFTPD SFTPB SCGB1A1 S100A12 IL6
3 specific granule lumen GO:0035580 9.33 SLPI ELANE CXCL1

Biological processes related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.01 SLPI SFTPD S100A12 MARCO HMGB1 CRP
2 neutrophil degranulation GO:0043312 10 SLPI S100A12 HMGB1 ELANE CXCL1
3 cellular protein metabolic process GO:0044267 9.89 SFTPD SFTPB IL6 CALCA
4 defense response to bacterium GO:0042742 9.89 SLPI SFTPD S100A12 ELANE DEFB4A
5 cellular response to lipopolysaccharide GO:0071222 9.8 IL6 HMGB1 CXCL8 CXCL1 CSF3
6 positive regulation of tumor necrosis factor production GO:0032760 9.79 IL6 HMGB1 CCL3
7 neutrophil chemotaxis GO:0030593 9.78 S100A12 CXCL8 CXCL1 CCL3
8 chemotaxis GO:0006935 9.77 HMGB1 DEFB4A CXCL8 CXCL1 CCL3
9 chemokine-mediated signaling pathway GO:0070098 9.76 CXCL8 CXCL1 CCL3
10 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.76 S100A12 DEFB4A CXCL8 CXCL1
11 positive regulation of interleukin-1 beta production GO:0032731 9.74 IL6 HMGB1 CCL3
12 response to glucocorticoid GO:0051384 9.73 SCGB1A1 IL6 IL22 HMGB1
13 cytokine-mediated signaling pathway GO:0019221 9.73 IL6 IL22 CXCL8 CXCL1 CSF3 CCL3
14 positive chemotaxis GO:0050918 9.72 HMGB1 DEFB4A CCL3
15 acute-phase response GO:0006953 9.7 IL6 IL22 CRP
16 immune response GO:0006955 9.7 SLPI IL6 DEFB4A CXCL8 CXCL1 CSF3
17 respiratory gaseous exchange GO:0007585 9.69 SFTPD SFTPB ELN
18 positive regulation of interleukin-8 production GO:0032757 9.62 IL6 HMGB1 ELANE CALCA
19 negative regulation of chemokine production GO:0032682 9.61 IL6 ELANE
20 negative regulation of lipid storage GO:0010888 9.58 IL6 CRP
21 positive regulation of myeloid cell differentiation GO:0045639 9.56 HMGB1 CSF3
22 inflammatory response GO:0006954 9.28 S100A12 IL6 IL22 HMGB1 CXCL8 CXCL1
23 monocyte chemotaxis GO:0002548 9.26 S100A12 IL6 CCL3 CALCA

Molecular functions related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.33 CXCL8 CXCL1 CCL3
2 RAGE receptor binding GO:0050786 9.26 S100A12 HMGB1
3 cytokine activity GO:0005125 9.17 IL6 IL22 HMGB1 CXCL8 CXCL1 CSF3
4 chemoattractant activity GO:0042056 9.13 HMGB1 DEFB4A CCL3

Sources for Bacterial Pneumonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....